DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Börse Stuttgart 11:56:41 2024-07-16 EDT | ||
| 1.47 EUR | +2.80% |
|
| 1 month | -4.67% | ||
| 3 months | +31.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-16 | 1.47 | +2.80% |
| 24-07-15 | 1.43 | -2.72% |
| 24-07-12 | 1.47 | -5.77% |
| 24-07-11 | 1.56 | +4.70% |
| 24-07-10 | 1.49 | -1.97% |
Delayed Quote Börse Stuttgart
Last update July 16, 2024 at 11:56 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7L |
| ISIN | DE000MG0D7L5 |
| Date issued | 2024-03-18 |
| Strike | 375 $ |
| Maturity | 2025-03-21 (248 Days) |
| Parity | 10 : 1 |
| Emission price | 1.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.73 € |
|---|---|
| Lowest since issue | 0.64 € |
| Spread | 0.06 € |
| Spread % | 3.95% |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
280
USD
Average target price
365.3
USD
Spread / Average Target
+30.50%
- Stock Market
- Certificates
- Certificat
